Calliditas Therapeutics AB (publ) is a biopharmaceutical company that develops pharmaceutical products for the treatment of renal and hepatic diseases, with a focus on rare, orphan indications. Its main products are Nefecon, an oral formulation of budesonide, and Setanaxib, a NOX inhibitor, currently in different clinical trial phases for treating various diseases. Additionally, the company develops Budenofalk 3mg oral capsules for autoimmune hepatitis.